"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs for the Treatment of Multiple System Atrophy."

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Centres
Trial History
References

Trial Profile

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs for the Treatment of Multiple System Atrophy."

Status: Suspended

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary) ; Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
Indications Multiple system atrophy
Focus Expanded access; Therapeutic Use
Sponsors Hope Biosciences

Most Recent Events

27 Nov 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com